Gelonghui, August 28th - Hengdi Pharmaceutical (301211.SZ) released its 2024 interim report, with half-year revenue of 0.242 billion yuan, a year-on-year decrease of 40.39%; net income attributable to shareholders of the listed company was 68.496 million yuan, a year-on-year decrease of 39.40%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 65.0419 million yuan, a year-on-year decrease of 40.87%; basic earnings per share was 0.24 yuan.
亨迪药业(301211.SZ)：上半年净利润6849.60万元 同比下降39.40%
Hengdi Pharmaceutical (301211.SZ): The net income in the first half of the year was 68.496 million yuan, a year-on-year decrease of 39.40%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.